JPMorgan Chase & Co. Raises Position in Sanofi (NASDAQ:SNY)

JPMorgan Chase & Co. increased its stake in shares of Sanofi (NASDAQ:SNY) by 20.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 2,310,809 shares of the company’s stock after purchasing an additional 399,301 shares during the quarter. JPMorgan Chase & Co. owned 0.09% of Sanofi worth $133,172,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Northwest Investment Counselors LLC bought a new stake in Sanofi in the third quarter worth about $29,000. Concord Wealth Partners raised its holdings in shares of Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after buying an additional 363 shares during the period. Sunbelt Securities Inc. lifted its stake in shares of Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after acquiring an additional 313 shares during the last quarter. Fortitude Family Office LLC boosted its holdings in Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after acquiring an additional 659 shares during the period. Finally, Ashton Thomas Private Wealth LLC bought a new position in Sanofi in the 2nd quarter valued at $51,000. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Analysts Set New Price Targets

SNY has been the subject of several research analyst reports. Citigroup upgraded Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Price Performance

Shares of SNY stock opened at $48.23 on Thursday. The stock has a market capitalization of $122.40 billion, a price-to-earnings ratio of 24.61, a P/E/G ratio of 1.23 and a beta of 0.58. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The stock has a fifty day simple moving average of $49.43 and a two-hundred day simple moving average of $52.05.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The company had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. During the same period in the prior year, the firm earned $2.55 earnings per share. The firm’s revenue for the quarter was up 12.3% compared to the same quarter last year. On average, analysts predict that Sanofi will post 4.06 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.